PONENTE研究:本瑞利珠单抗治疗重度嗜酸性哮喘中口服糖皮质激素个体化减停算法
PONENTE是一项多中心、开放标签、单臂研究,纳入598例需维持口服糖皮质激素的重度嗜酸性哮喘成人患者,在接受本瑞利珠单抗治疗后采用快速个体化激素减量算法(含肾上腺功能监测)。肾上腺功能不全发生率较高,但安全性总体可控。
要点
- 本瑞利珠单抗联合个体化减量算法可使多数重度嗜酸性哮喘患者停用口服激素。
- 减量方案需监测肾上腺功能,因肾上腺功能不全发生率较高(首次评估60%)。
核心结论
- 尽管肾上腺功能不全患病率高,多数接受本瑞利珠单抗治疗的嗜酸性哮喘患者通过个体化减量算法可停用口服糖皮质激素或达到最大程度减量。
研究设计与样本
- 多中心、开放标签、单臂研究,在17个国家138个临床哮喘治疗中心进行。
- 纳入598例成人重度嗜酸性哮喘患者(年龄≥18岁,血嗜酸性粒细胞计数≥150 cells/μL入组时或既往一年≥300 cells/μL),需维持口服糖皮质激素至少3个月。
- 患者接受本瑞利珠单抗30 mg皮下注射,每4周一次共3次,之后每8周一次。
- 口服激素减量从第4周开始,根据起始剂量、哮喘控制和肾上腺功能状态,每1-4周减少1-5 mg/日。
- 主要终点为停用每日口服激素并维持至少4周的患者百分比,以及若因肾上腺功能不全停止减量则达到停用或每日泼尼松/泼尼松龙剂量≤5 mg并维持至少4周的患者百分比。
主要发现
- 亚组分析显示减量效果与基线嗜酸性粒细胞计数、基线口服激素剂量或口服激素治疗持续时间无关。
- 533例患者中,321例(60%)首次评估发现肾上腺功能不全,205例(38%)在2-3个月后复查时发现。
临床怎么用
- 对接受本瑞利珠单抗治疗的重度嗜酸性哮喘患者,可采用个体化口服激素减量算法,每1-4周减少1-5 mg/日。
- 减量过程中需监测肾上腺功能,尤其在每日口服激素剂量达到5 mg/日并维持4周时,应检测清晨血清皮质醇,必要时行促肾上腺皮质激素刺激试验。
- 减量方案应根据哮喘控制(每周ACQ-6评估)和肾上腺功能状态调整。
局限性
- 本研究为单臂、开放标签设计,无对照组。
- 结果仅报告口服激素减量阶段,维持阶段仍在进行中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No consensus exists on how to reduce oral corticosteroids after the initiation of biologics in severe asthma. The PONENTE trial evaluated the effectiveness and safety of a rapid, individualised steroid-reduction algorithm, including adrenal insufficiency monitoring, after benralizumab initiation. METHODS: This multicentre, open-label, single-arm study was done at 138 clinical asthma treatment centres across 17 countries. We enrolled adult patients (age ≥18 years) with severe, eosinophilic asthma (blood eosinophil count ≥150 cells per μL at enrolment or ≥300 cells per μL in the previous year) requiring maintenance oral corticosteroids for at least 3 months preceding enrolment. Patients received benralizumab 30 mg (subcutaneous injection) every 4 weeks for three doses, then every 8 weeks thereafter. The oral corticosteroid reduction phase began at week 4 with daily oral corticosteroid dosages reduced by 1-5 mg every 1-4 weeks depending on the starting dosage, asthma control, and adrenal function status. Adrenal function was assessed with an early morning serum cortisol measurement, followed by adrenocorticotropic hormone stimulation when required, once patients achieved a daily oral corticosteroid dosage of 5 mg/day for 4 weeks. Repeat cortisol measurements were taken for patients with evidence of adrenal insufficiency at first testing. Asthma control was assessed with the Asthma Control Questionnaire-6 (ACQ-6) weekly throughout the induction and oral corticosteroid reduction phases. The primary endpoints were the percentage of patients eliminating daily oral corticosteroids, sustained for at least 4 weeks, and the percentage achieving elimination or a daily prednisone or prednisolone dosage of 5 mg or less, for at least 4 weeks, if the reason for no further reduction was adrenal insufficiency. Safety and efficacy analyses included all patients who received at least one dose of benralizumab and were descriptive. We present results after the oral corticosteroid reduction phase; a maintenance phase is ongoing. The trial is registered with ClinicalTrials.gov, NCT03557307. FINDINGS: Between April 1, 2018, and Sept 5, 2020, of 705 patients assessed for eligibility, 598 were recruited and all received at least one dose of benralizumab. Overall, 376 (62·88%, 95% CI 58·86-66·76) of 598 patients eliminated oral corticosteroids and 490 (81·94%, 78·62-84·94) of 598 eliminated use or achieved a dosage of 5 mg or less if the reason for stopping the reduction was adrenal insufficiency. Subgroup analysis showed that dosage reductions were achieved irrespective of baseline eosinophil count, baseline oral corticosteroid dosage, or oral corticosteroid treatment duration. Adrenal insufficiency was detected in 321 (60%) of 533 patients at first assessment and in 205 (38%) of 533 patients 2-3 months later. The safety profile was consistent with previous experience. Most patients (448 [75%] of 598) had no asthma exacerbations during the oral corticosteroid reduction phase with an annualised exacerbation rate of 0·63. Of 598 patients, 38 (6%) experienced a total of 46 exacerbations resulting in emergency department or urgent care visits or hospitalisations. INTERPRETATION: Despite a high prevalence of adrenal insufficiency, most patients with eosinophilic asthma treated with benralizumab achieved elimination of oral corticosteroids or maximal possible reduction using a personalised dosage-reduction algorithm. FUNDING: AstraZeneca.
引用
- Menzies-Gow A, Gurnell M, Heaney LG, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2021. PMID: 34619104. doi:10.1016/S2213-2600(21)00352-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。